-
FINAL RESULTS ANNOUNCEMENT for the year ended 31 December 2022
ImmuPharma PLC (LSE:IMM), (“ImmuPharma” or the “Company”), the specialist drug discovery and development company, is pleased to announce its final results for the twelve months ended 31 December 2022 (the “Period”). Key Highlights (including post Period review) Financial Loss for the Period of £3.8m (2021: £8.2m) Research and development expenses of £2.0m (2021: £3.7m) Administrative expenses of £0.8m…
-
Proactive Interview – Tim McCarthy
Proactive – ImmuPharma “looking forward” to upcoming FDA meetings 27 April 2023 Tim McCarthy, CEO talks to Proactive on recent positive newsflow and his optimism on the forthcoming FDA meetings for Lupuzor for lupus and CIDP – 27 April 2023
-
FDA confirms Type-C meeting date of 7th June 2023 for Phase 2/3 adaptive study of Lupuzor™ in lupus
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce that the Food and Drug Administration (“FDA”) has set a date of 7th June 2023 for a Type-C meeting to provide guidance on the Phase 2/3 adaptive study of Lupuzor™ (“P140”) in patients with systemic lupus erythematosus (“SLE/Lupus”). This follows on…
-
ImmuPharma receives confirmation of pre-IND meeting date with FDA for a Phase 2/3 adaptive study of P140 in CIDP
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is pleased to announce further positive progress in its late-stage P140 clinical program in patients with chronic idiopathic demyelinating polyneuropathy (“CIDP”). Key highlights: ImmuPharma has received confirmation from the Food and Drug Administration (“FDA”) for a pre- Investigational New Drug meeting date of 16 May…
-
Avion submits clinical protocol of Phase 2/3 adaptive study of Lupuzor™ in lupus to FDA
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to update the market on the next positive step in its Lupuzor™ (P140) program in patients with systemic lupus erythematosus (“SLE/Lupus”). This follows on from the recent announcement on 6 February 2023. Key highlights Avion Pharmaceuticals (“Avion”) and ImmuPharma agreed in February on…
-
Collaboration with Orano on ImmuPharma’s peptide technology as a vector for cancer radiotherapy
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, is delighted to announce that it has signed an initial collaboration agreement on the Company’s peptide technology, with Orano SA (“Orano”), a leading international corporation and a key player in the nuclear energy sector. Key points: Orano has paid a small undisclosed amount to ImmuPharma…
-
-
Phase 2/3 adaptive study design for Lupus study agreed with Avion
ImmuPharma PLC (LSE:IMM), the specialist drug discovery and development company, provides an update to the market on its Lupuzor™ programme in patients with systemic lupus erythematosus (“SLE”) Key highlights: In conjunction with its partner Avion Pharmaceuticals (“Avion”), ImmuPharma confirms that a Phase 2/3 adaptive trial will be the best design for the next clinical study…
